hVIVO (LON:HVO) Shares Down 7.2% – Should You Sell?

hVIVO plc (LON:HVO)’s share price was down 7.2% on Monday. The company traded as low as GBX 5.91 and last traded at GBX 6.08. 2,399,280 shares traded hands during trading, a decline of 4% from the average daily volume of 2,505,322 shares. The stock had previously closed at GBX 6.55.

hVIVO Stock Down 7.2%

The company has a market cap of £41.83 million, a PE ratio of -6.99 and a beta of 1.69. The business’s 50 day moving average is GBX 6.71 and its 200-day moving average is GBX 7.29. The company has a debt-to-equity ratio of 43.38, a current ratio of 1.21 and a quick ratio of 1.16.

hVIVO (LON:HVO) last posted its earnings results on Tuesday, September 15th. The company reported GBX (0.82) EPS for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. As a group, analysts predict that hVIVO plc will post 1.5492958 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.